The rising incidence of atrial fibrillation (AF) is increasingly resulting in a substantial worldwide increase in AF-related stroke, particularly in elderly patients and this is creating an increasingly serious healthcare burden. Guidelines recommend the use of AF-related stroke prophylaxis but adherence to these remains poor. Studies conducted in the 1990s showed that warfarin reduced the risk of AF-related stroke by an overall 64% compared with placebo. Subsequently, prophylactic treatment was further improved with the development of non-vitamin K antagonist oral anticoagulants (NOACs). More recently, a meta-analysis of four large clinical trials on NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) showed there was a relative risk reduction of 0.81 (p<0.0001) favouring NOAC treatment over warfarin for stroke or systemic embolic events in patients with AF. The largest trial of NOACs in AF-related stroke, to date, was the ENGAGE AF-TIMI 48 study (n=21,105) which showed that edoxaban was non-inferior to warfarin for ischaemic stroke reduction but significantly reduced bleeding and cardiovascular mortality. A recent subgroup analysis of this study showed that with edoxaban the incidences of intracranial haemorrhage (ICH) subtypes (all ICH, fatal ICH, fatal, subdural and epidural bleed) were significantly lower with 60 mg of edoxaban (p=0.013–<0.001). Edoxaban was also shown to be an effective option in patients with prior stroke. In addition edoxaban was shown to reduce deaths due to fatal bleeds compared with warfarin. The results of current studies, especially the ENGAGE AF-TIMI 48 subgroup analysis therefore, show that the benefits of anticoagulation therapy in patients with AF substantially outweigh the risks
Atrial fibrillation-related stroke, outcomes, non-vitamin K oral anticoagulants (NOACs)
Peter Kelly has served on advisory boards or received speakers fees or benefits from the American Stroke Association, Bayer and Daiichi Sankyo, and has received research unit grants from the Health Research Board of Ireland, Irish Heart Foundation and Bayer. Carlos Molina has nothing to declare in relation to this article. Christian T. Ruff has received research support from GlaxoSmithKline, Daiichi Sankyo, Intarcia and AstraZeneca, and serves as a consultant and on the advisory boards for Boehringer Ingelheim, Bayer, Daiichi Sankyo, Portola and DrugDev. Roland Veltkamp has received speaker fees, consulting honoraria and research support from Bayer, Boehringer Ingelheim, BMS, Pfizer, Daiichi Sankyo, CSL Behring, Apoplex Medical Technologies, Morphosys, Biogen, Medtronic.
Editorial assistance was provided by James Gilbart at Touch Medical Media, London, this was supported by an unrestricted grant from Daiichi Sankyo Europe GmbH. This article reports the proceedings of a sponsored satellite symposium and as such has not been subject to the journal’s usual peer-review process
This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit
October 16, 2015 Accepted:
February 19, 2016
Peter Kelly, Stroke Service and NeuroVascular Unit for Translational and Therapeutics Research, University College Dublin, Ireland E: email@example.com.
The publication of this article was supported by Daiichi Sankyo Europe GmbH. The views and opinions expressed are those of the authors and not necessarily
those of Daiichi Sankyo Europe GmbH.
In atrial fibrillation (AF), considerable harm can result from the lack of appropriate preventive therapy, and optimal prevention is critical, especially in vulnerable elderly or frail patients. AF markedly increases the risk of stroke and this condition must be monitored and potentially treated wherever it is detected.1–4 AF is an increasing concern for physicians worldwide as populations age and more people are at risk.5–7 Although guidelines for stroke prevention in AF that recommend anticoagulation have been established for many years, many at-risk patients receive inadequate anticoagulation or none at all.8–11 This ‘reluctance to treat’ stems largely from a fear of inducing intracranial haemorrhage (ICH) and other serious bleeding types that are associated with warfarin and the non–vitamin K antagonist oral anticoagulants (NOACs). This risk, however, is often over-stated and substantially less than the risks that are associated with the lack of stroke prevention treatment in AF. This review discusses the burden of AF-related stroke and evidence that supports current treatments, and considers novel insights on the use of edoxaban as provided by recent subgroup analyses of the ENGAGE AF-TIMI 48 trial results (see end of article for trial name definitions). These topics were presented at a satellite symposium convened at the European Stroke Organisation Annual Meeting in Glasgow, UK, in April 2015.
Preventing the Rise of AF-related Stroke– A Call to Action
Large-scale population-based observational studies have shown AF to be a serious factor increasing the likelihood of strokes and substantially worsening mortality and morbidity after a stroke.12 Various studies have predicted increasing incidence and prevalence of AF-related stroke and the associated heavy burden this will place on healthcare authorities worldwide. Professor Peter Kelly assessed the history and rising incidence of AF-related stroke. His message constitutes a call to action, encouraging physicians to treat all patients with AF to help stem the burgeoning number of ischaemic strokes and reduce the burden strokes impose on healthcare services.
1. Barra S, Fynn S, Untreated atrial fibrillation in the United Kingdom: understanding the barriers and treatment options, J Saudi Heart Assoc, 2015;27:31–43.
2. Lip GY, Lim HS, Atrial fibrillation and stroke prevention, Lancet Neurol, 2007;6:981–93.
3. Sposato LA, Cipriano LE, Saposnik G, et al., Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis, Lancet Neurol, 2015;14:377–87.
4. Verdino RJ, Untreated atrial fibrillation in the United States of America: Understanding the barriers and treatment options, J Saudi Heart Assoc, 2015;27:44–9.
5. Go AS, Hylek EM, Phillips KA, et al., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, JAMA, 2001;285:2370–5.
6. Moukabary T, Gonzalez MD, Management of atrial fibrillation, Med Clin North Am, 2015;99:781–94.
7. Murphy NF, Simpson CR, Jhund PS, et al., A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland, Heart, 2007;93:606–12.
8. Camm AJ, Lip GY, De Caterina R, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation, developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, 2012;33:2719–47.
9. European Heart Rhythm A, European Association for CardioThoracic S, Camm AJ, et al., Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 2010;31:2369–429.
10. Fuster V, Rydén LE, Cannom DS, et al., ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary, Circulation, 2006;114:700–52.
11. Heidbuchel H, Verhamme P, Alings M, et al., European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace, 2013;15:625–51.
12. Steger C, Pratter A, Martinek-Bregel M, et al., Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry, Eur Heart J, 2004;25:1734–40.
13. Friedberg CK, Diseases of the heart, 3rd edition, Philadelphia: Saunders, 1996.
14. Lee GA, Stub D, Ling H, Atrial fibrillation in the elderly: not a benign condition, Int Emerg Nurs, 2012;20:221–7.
15. Fisher C, Treatment of chronic atrial fibrillation, Lancet Neurol, 1972;299:1284.
16. Wolf PA, Awareness of the role of atrial fibrillation as a cause of ischemic stroke, Stroke, 2014;45:e19–21.
17. Wolf PA, Dawber TR, Thomas HE, Jr, et al., Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study, Neurology, 1978;28:973–7.
18. Chugh SS, Havmoeller R, Narayanan K, et al., Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study, Circulation, 2014;129:837–47.
19. Sacco RL, Boden-Albala B, Abel G, et al., Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study, Stroke, 2001;32:1725–31.
20. Miyasaka Y, Barnes ME, Gersh BJ, et al., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence, Circulation, 2006;114:119–25.
21. Hannon N, Sheehan O, Kelly L, et al., Stroke associated with atrial fibrillation – incidence and early outcomes in the north Dublin population stroke study, Cerebrovasc Dis, 2010;29:43–9.
22. European Registers of Stroke I, Heuschmann PU, Di Carlo A, et al., Incidence of stroke in Europe at the beginning of the 21st century, Stroke, 2009;40:1557–63.
23. Rothwell PM, Coull AJ, Giles MF, et al., Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford vascular study), Lancet, 2004;363:1925–33.
24. Friberg L, Rosenqvist M, Lindgren A, et al., High prevalence of atrial fibrillation among patients with ischemic stroke, Stroke, 2014;45:2599–605.
25. Kelly PJ, Crispino G, Sheehan O, et al., Incidence, event rates, and early outcome of stroke in Dublin, Ireland: the North Dublin population stroke study, Stroke, 2012;43:2042–7.
26. Hannon N, Daly L, Murphy S, et al., Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation: population-based study, Stroke, 2014;45:3670–4.
27. Gladstone DJ, Bui E, Fang J, et al., Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated, Stroke, 2009;40:235–40.
28. Yiin GS, Howard DP, Paul NL, et al., Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a populationbased study, Circulation, 2014;130:1236–44.
29. Miyasaka Y, Barnes ME, Gersh BJ, et al., Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study, Stroke, 2005;36:2362–6.
30. Ng KH, Hart RG, Eikelboom JW, Anticoagulation in patients aged >/=75 years with atrial fibrillation: role of novel oral anticoagulants, Cardiol Ther, 2013;2:135–49.
31. Morley J, Marinchak R, Rials SJ, et al., Atrial fibrillation, anticoagulation, and stroke, Am J Cardiol, 1996;77:38A–44A.
32. Ruff CT, Giugliano RP, Braunwald E, et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 2014;383:955–62.
33. Gage BF, Waterman AD, Shannon W, et al., Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation, JAMA, 2001;285:2864–70.
34. Lip GY, Nieuwlaat R, Pisters R, et al., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation, Chest, 2010;137:263–72.
35. Stroke Prevention in Atrial Fibrillation Investigators, Design of a multicenter randomized trial for the stroke prevention in atrial fibrillation study, Stroke, 1990;21:538–45.
36. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation, N Engl J Med, 1990;323:1505–11.
37. Connolly SJ, Laupacis A, Gent M, et al., Canadian atrial fibrillation anticoagulation (CAFA) study, J Am Coll Cardiol, 1991;18:349–55.
38. Ezekowitz MD, Bridgers SL, James KE, et al., Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation, N Engl J Med, 1992;327:1406–12.
39. Petersen P, Boysen G, Godtfredsen J, et al., Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study, Lancet, 1989;1:175–9.
40. European Atrial Fibrillation Trial Study Group, Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke, Lancet, 1993;342:1255–62.
41. Pisters R, Lane DA, Nieuwlaat R, et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 2010;138:1093–100.
42. van Etten ES, Auriel E, Haley KE, et al., Incidence of symptomatic hemorrhage in patients with lobar microbleeds, Stroke, 2014;45:2280–5.
43. Hylek EM, Singer DE, Risk factors for intracranial hemorrhage in outpatients taking warfarin, Ann Intern Med, 1994;120:897–902.
44. Hylek EM, Skates SJ, Sheehan MA, et al., An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation, N Engl J Med, 1996;335:540–6.
45. Connolly SJ, Ezekowitz MD, Yusuf S, et al., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 2009;361:1139–51.
46. Giugliano RP, Ruff CT, Braunwald E, et al., Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 2013;369:2093–104.
47. Granger CB, Alexander JH, McMurray JJ, et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 2011;365:981–92.
48. Greenspon AJ, A review of oral anticoagulants in patients with atrial fibrillation, Postgrad Med, 2012;124:7–16.
49. 49. Patel MR, Mahaffey KW, Garg J, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 2011;365:883–91.
50. Verheugt FW, Granger CB, Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs, Lancet, 2015;386(9990):303–10.
51. Dewilde WJ, Oirbans T, Verheugt FW, et al., Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet, 2013;381:1107–15.
52. Lamberts M, Gislason GH, Olesen JB, et al., Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention, J Am Coll Cardiol, 2013;62:981–9.
53. Mauri L, Kereiakes DJ, Yeh RW, et al., Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents, N Engl J Med, 2014;371:2155–66.
54. Gibson CM, Mehran R, Bode C, et al., An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI), Am Heart J, 2015;169:472–8 e5.
55. Boehringer Ingelheim, Evaluation of dual therapy with dabigatran vs triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI) NCT02164864, 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT 02164864?term=NCT02164864&rank=1 date (Accessed 5 May 2015).
56. Giugliano RP, Ruff CT, Rost NS, et al., Cerebrovascular events in 21,105 patients with atrial fibrillation randomized to edoxaban versus warfarin: effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48, Stroke, 2014;45:2372–8.
57. Rost NS, Giugliano RP, Ruff CT, et al., Efficacy and safety of edoxaban vs warfarin in high-risk patients: the ENGAGE AFTIMI 48 trial WSC-1119, Int J Stroke, 2014;9(Suppl. 3):38.
58. Ruff CT, Giugliano RP, Braunwald E, et al., Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, doubleblind ENGAGE AF-TIMI 48 trial, Lancet, 2015;385:2288–95.
59. Giugliano RP, Ruff CT, Wiviott SD, et al., Reduction in bleeding with edoxaban vs warfarin linked to lower all-cause mortality in 21,105 patients randomized in the ENGAGE AF-TIMI 48 trial, Eur Heart J, 2014;35(Suppl. 1):867.
60. Friberg L, Rosenqvist M, Lip GY, Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study, Circulation, 2012;125:2298–307.
61. Man-Son-Hing M, Nichol G, Lau A, et al., Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med, 1999;159:677–85.
62. Donze J, Clair C, Hug B, et al., Risk of falls and major bleeds in patients on oral anticoagulation therapy, Am J Med, 2012;125:773–8.
63. Hart RG, Pearce LA, Aguilar MI, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 2007;146:857–67.
64. Bonita R, Beaglehole R, Recovery of motor function after stroke, Stroke, 1988;19:1497–500.
65. Stroke Prevention in Atrial Fibrillation Investigators, Stroke prevention in atrial fibrillation study: final results, Circulation, 1991;84:527–39.